

Claims:

1. A method of stimulating the immune system of a subject which comprises administering to the subject an immunologically effective amount of an immunostimulatory molecule which comprises at least one oligonucleotide strand which comprises

(1) at least one nucleotide sequence comprising a plurality of nucleotides, each nucleotide comprising a nucleobase, and thereby also comprising at least one CxG dinucleotide unit or analogue thereof, and

(2) at least one covalently incorporated lipophilic group.

2. The method of claim 1 in which element (1) comprises a CxG dinucleotide unit.

3. The method of claims 1 or 2 in which the CxG dinucleotide unit is a CpG dinucleotide unit.

4. The method of any one of claims 1-3 in which at least one lipophilic group is a strongly lipophilic group.

5. The method of any one of claims 1-4 in which at least one lipophilic group is a highly lipophilic (Meylan) group.

6. The method of any one of claims 1-5 in which at least one lipophilic group has a predicted logP, according to the Meylan algorithm, of at least 4.

7. The method of any one of claims 1-5 in which at least one lipophilic group has a predicted logP, according to the Meylan algorithm, of at least 7.


BEST AVAILABLE COPY

8. The method of any one of claims 1-5 in which at least one lipophilic group has a predicted logP, according to the Meylan algorithm, of at least 10.

5 9. The method of any one of claims 1-8 in which at least one lipophilic group is selected from the group consisting of


(a)

10



where n = an integer with values ranging from 6 to 26,

15 (b)



where m and n are independent integers with values ranging from 6 to 26,

20

(c)


-XR wherein X is -O-, -S-, or -NH- and -R is aliphatic,

(d)

-XR wherein X is -O-, -S-, or -NH- and -R is at least
25 partially aromatic,

10. The method of claim 9 where -R is a group selected from the group consisting of one of the following structures:

30



where m , n , and k are independent integers with values ranging from 3 to 30.

- 5 11. The method of any one of claims 1-9 in which at least one lipophilic group is one of the lipophilic groups depicted in Fig. 2.
- 10 12. The method of any one of claims 1-11 where said molecule comprises at least two lipophilic groups.
13. The method of claim 12 where said molecule comprises at least two strongly lipophilic groups.
- 15 14. The method of claim 12 where said molecule comprises at least two highly lipophilic (Meylan) groups.

15. The method of any one of claims 1-14 in which there are fewer than 8 nucleobases on each nucleotide strand.

5 16. The method of claim 15 in which there are fewer than 5 nucleobases on each nucleotide strand.

10 17. The method of any one of claims 1-16 in which each of the nucleobases is selected from the group consisting of adenine, guanine, thymine, cytosine, uracil, and hypoxanthine.

15 18. The method of any one of claims 1-16 in which each of the nucleobases is selected from the group consisting of adenine, guanine, thymine, and cytosine.

19. The method of any one of claims 1-18 wherein at least one nucleotide comprises a nucleobase-carbohydrate nucleoside.

20 20. The method of claim 19 in which the carbohydrate is a monosaccharide.

25 21. The method of claim 19 in which the number of carbon atoms in the monosaccharide is 3-8.

22. The method of claim 21 in which the monosaccharide is a pentose.

30 23. The method of any one of claims 20-22 in which the monosaccharide is an aldose.

24. The method of any one of claims 20-23 in which the monosaccharide is cyclized.

25. The method of claim 19 in which the monosaccharide is a pyranose.

5

26. The method of claim 20 in which the monosaccharide is a ribose or a 2-deoxyribose.

10 27. The method of any one of claims 1-26 in which all of the nucleotides of one strand comprise a nucleobase-carbohydrate nucleoside.

15 28. The method of any one of claims 1-27 in which at least one nucleotide further comprises a phosphate.

29. The method of claim 28 in which at least one nucleotide comprises one and only one phosphate.

20 30. The method of claim 29 in which at least one strand is DNA or RNA.

25 31. The method of any one of claims 1-30 in which at least one lipophilic group is covalently incorporated into a free end of at least one strand.

32. The method of any one of claims 1-31 in which at least one lipophilic group is covalently incorporated into the 3' end of at least one strand.

30

33. The method of claims 31 or 32 in which the lipophilic group is attached to the end through a phosphate group.

34. The method of any one of claims 1-33 in which at least one lipophilic group is incorporated into an internucleoside linkage.

5 35. The method of any one of claims 1-34 in which at least one lipophilic group is a substituent of a nucleobase.

10 36. The method of any one of claims 1-35 in which at least part of the oligonucleotide has a backbone which differs from that of DNA and RNA.

15 37. The method of claim 36 in which the backbone differs in that the internucleoside linkage is not a phosphate group.

20 38. The method of claim 36 in which the backbone differs in that at least one nucleotide is a non-normal nucleotide which does not comprise ribose or 2-deoxyribose.

39. The method of claim 38 in which the non-normal nucleoside comprises a sugar.

25 40. The method of claim 38 in which the non-normal nucleotide does not comprise a sugar.

41. The method of claim 40 in which the oligonucleotide is at least partially a PNA oligomer.

30 42. The method of claim 40 in which at least one non-normal nucleotide comprises a non-normal nucleoside of the form

nucleobase-O-alkyl

35

where the -O-alkyl is the residue of a polyol, and the alkyl is not more than 6 carbon atoms.

5 43. The method of claim 42 wherein the polyol is glycerol, and hence the alkyl is 3 carbon atoms.

10 44. The method of any one of claims 36-40, 42 or 43 in which at least non-normal nucleoside is bound to a phosphate group.

45. The method of claim 44 in which there are two adjacent such non-normal nucleosides and the internucleoside linkage between them is a phosphate group.

15 46. The method of claim 44 in which there are two adjacent such non-normal nucleosides and the internucleoside linkage between them is

-phosphate group-linker Z-phosphate group-,

20 where linker Z is aliphatic.

25 47. The method of claim 46 in which linker Z is of the form $-\{\text{small alkyl-O}\}_n$, where n is 1 to 20, and small alkyl is not more than 6 carbon.

48. The method of claim 47 in which linker Z is $-\text{[CH}_2\text{CH}_2\text{O]}_n-$.

30 49. The method of any one of claims 1-48 in which the dinucleotide unit comprises a non-natural nucleoside, or an internucleoside linkage which is not a phosphate group.

35 50. The method of any one of claims 1-48 in which the CxG dinucleotide unit comprises two non-natural nucleosides

and the internucleoside linkage between them is a phosphate group.

5 51. The method of claim 49 in which the dinucleotide unit comprises two non-natural nucleosides and the internucleoside linkage between them is

-phosphate group-linker Z-phosphate group-,

10 where linker Z is aliphatic.

52. The method of claim 51 in which linker Z is -
[CH₂CH₂O]_n- and n is 1 to 20.

15 53. The method of claim 49 in which the dinucleotide unit is a PNA oligomer.

54. The method of claim 49 in which the dinucleotide unit is a GNA oligomer.

20

55. The method of any one of claims 1-54 in which the molecule lacks double stranded structure.

25 56. The method of any one of claims 1-54 in which the molecule has at least some double stranded structure.

57. The method of any one of claims 1-56 in which there are no more than seven nucleobases in each oligonucleotide strand.

30

58. The method of any one of claims 1-56 in which there are no more than four nucleobases in each oligonucleotide strand.

59. The method of any one of claims 1-58 in which the molecule further comprises at least one epitope.

5 60. The method of claim 59 wherein at least one epitope is a carbohydrate epitope.

61. The method of claim 59 or 60 wherein at least one epitope is a peptide epitope.

10 62. The method of any one of claims 59-61 wherein at least one epitope is a B-cell epitope.

63. The method of any one of claims 59-62 wherein at least one epitope is a T-cell epitope.

15 64. The method of any one of claims 59-63 wherein at least one epitope is a MUC1 epitope.

20 65. The method of any one of claims 1-64 in which the oligonucleotide is cyclized, so as to lack a free end, and the lipophilic groups are incorporated elsewhere in the molecule.

25 66. The method of any one of claims 1-64 where said molecule which comprises two or more segments, each segment consisting of nucleosides joined to each other by short internucleoside linkages, each segment being joined to at least one other segment by a long internucleoside linkage,

30 at least two of said segments each comprising at least one CxG dinucleotide unit or analogue thereof.


67. The method of claim 66 in which said segments are connected by said internucleoside linkages to form one or more linear chains.

5 68. The method of claim 66 in which two or more segments are cyclized by two or more internucleoside linkages.

69. The molecule of claim 66 in which at least one internucleoside linkage is a higher order linkage which
10 simultaneously links three or more segments to each other, whereby said segments are connected to form a branched structure.

70. The molecule of claim 66 in which at least one
15 internucleoside linkage comprises a pentaerythritol unit

71. The molecule of claim 66 in which the molecule has the following structural feature



20 wherein R is a lipophilic group; A₁, A₂ and A₃ are independently a linking arm of 0 to 20 atoms length; R₁, R₂ and R₃ are independently chosen from the group consisting of a hydrogen atom, a lipophilic group or an oligonucleotide residue.

72. The method of any one of claims 1-71 where said nucleotide sequence comprises at least one pair of adjacent thymine nucleobases which are dimerized to form a thymine dimer.

5

73. The method of any one of claims 1-72 in which at least one lipophilic group is covalently incorporated into the 5' end of an oligonucleotide strand.

10

74. The method of any one of claims 1-73 in which the molecule does not have cytotoxic activity against cancer cells.

15

75. The method of any one of claims 1-74 in which the subject is not suffering from a cancer.

76. The method of any one of claims 1-75 in which the subject is not being medicated with any otehr cancer preventative.

20

77. The method of any one of claims 1-76 in which the molecule potentiates the specific innate immune response to a pathogen or cancer already present in the subject.

25

78. The method of any one of claims 1-76 which further comprises administering a pharmaceutical composition comprising an immunogen to the subject, said molecule potentiating the specific elicited immune response to said immunogen.

30

79. The method of claim 78 in which the molecule and the immunogen are administered simultaneously.

35

80. The method of claim 79 in which the molecule and the immunogen are administered in the same composition.

81. The method of claim 78 in which the immunostimulatory oligonucleotide molecule is also an immunogen which elicits a specific immune response protective against said pathogen or cancer.

5

82. Use of an immunostimulatory molecule as defined in any one of claims 1-74 in the manufacture of a composition for immunostimulating a subject.

10

83. An immunostimulatory molecule which comprises at least one oligonucleotide strand, said strand comprising a nucleotide sequence, the nucleotide sequence comprising a plurality of nucleotides, each nucleotide comprising a nucleobase, and thereby also comprising at least one CxG dinucleotide unit or analogue thereof, and

15

(2) at least one covalently incorporated lipophilic group,

where the number of nucleotides in said strand is less than eight.

20

84. The molecule of claim 83 where the nature of said molecule is further limited in accordance with any one of claims 2-75.

25

85. An immunostimulatory molecule which comprises (I) at least one oligonucleotide strand which comprises

(1) at least one nucleotide sequence comprising a plurality of nucleotides, each nucleotide comprising a nucleobase, and thereby also comprising at least one CxG dinucleotide unit or analogue thereof, and

30

(2) at least one covalently incorporated lipophilic group, and

(II) an epitope.

35

86. The molecule of claim 85 wherein at least one epitope is a carbohydrate epitope.

5 87. The molecule of claim 85 or 86 wherein at least one epitope is a peptide epitope.

88. The molecule of any one of claims 85-87 wherein at least one epitope is a B-cell epitope.

10 89. The molecule of any one of claims 85-88 wherein at least one epitope is a T-cell epitope.

90. The molecule of any one of claims 85-89 wherein at least one epitope is a MUC1 epitope.

15

91. The molecule of any one of claims 85-90 where the nature of said molecule is further limited in accordance with any one of claims 2-59.

20 92. An immunostimulatory molecule which comprises (I) at least one oligonucleotide strand which comprises

(1) at least one nucleotide sequence comprising a plurality of nucleotides, each nucleotide comprising a nucleoside, each nucleoside comprising a nucleobase, each
25 nucleoside being joined to at least one other nucleoside by an internucleoside linkage,

said molecule comprising two or more segments, each segment consisting of nucleosides joined to each other by
30 short internucleoside linkages, each segment being joined to at least one other segment by a long internucleoside linkage,

at least two of said segments each comprising at least one
35 CxG dinucleotide unit or analogue thereof, and

(2) at least one covalently incorporated lipophilic group.


93. The molecule of claim 92 in which said segments are connected by said internucleoside linkages to form one or more linear chains.

94. The molecule of claim 92 in which one or more segments are connected by one or more of said long internucleoside linkages to form a cyclic structure.

95. The molecule of claim 92 in which at least one internucleoside linkage is a higher order linkage which simultaneously links three or more segments to each other, whereby said segments are connected to form a branched structure.

96. The molecule of claim 92 in which at least one internucleoside linkage comprises a pentaerythritol unit

97. The molecule of claim 92 in which the molecule has the following structural feature



wherein R is a lipophilic group; A_1 , A_2 and A_3 are independently a linking arm of 0 to 20 atoms length; R_1 , R_2 and R_3 are independently chosen from the group consisting

of a hydrogen atom, a lipophilic group or an oligonucleotide residue.

5 98. The molecule of any one of claims 92-97 where the nature of the molecule is further limited in accordance with any one of claims 2-64.

10 99. An immunostimulatory molecule which comprises at least one oligonucleotide strand, said strand comprising
(1) a nucleotide sequence, the nucleotide sequence comprising a plurality of nucleotides, each nucleotide comprising a nucleobase, and thereby also comprising at least one CxG dinucleotide unit or analogue thereof, and
15 (2) at least one covalently incorporated lipophilic group,

where said nucleotide sequence comprises at least one pair of adjacent thymine nucleobases which are dimerized to form a thymine dimer.

20

100. The method of any one of claims 1-81 where none of the internucleoside linkages is selected from the group consisting of poly(N-vinyl), poly(methacyloxyethyl), poly(methacrylamide), and poly(ethyleneimine).

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.